SXTP vs. DRRX, SNYR, NKGN, BFRG, MRKR, PMN, PRPH, GOVX, GELS, and LPTX
Should you be buying 60 Degrees Pharmaceuticals stock or one of its competitors? The main competitors of 60 Degrees Pharmaceuticals include DURECT (DRRX), Synergy CHC Corp. (Uplisting) (SNYR), NKGen Biotech (NKGN), Bullfrog AI (BFRG), Marker Therapeutics (MRKR), ProMIS Neurosciences (PMN), ProPhase Labs (PRPH), GeoVax Labs (GOVX), Gelteq (GELS), and Leap Therapeutics (LPTX). These companies are all part of the "pharmaceutical products" industry.
60 Degrees Pharmaceuticals vs. Its Competitors
DURECT (NASDAQ:DRRX) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, community ranking, institutional ownership, valuation, risk, analyst recommendations and earnings.
60 Degrees Pharmaceuticals has lower revenue, but higher earnings than DURECT. DURECT is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
60 Degrees Pharmaceuticals has a net margin of 0.00% compared to DURECT's net margin of -198.58%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat DURECT's return on equity.
DURECT has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.89, meaning that its stock price is 189% more volatile than the S&P 500.
28.0% of DURECT shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 3.2% of DURECT shares are owned by insiders. Comparatively, 10.3% of 60 Degrees Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
60 Degrees Pharmaceuticals has a consensus price target of $7.00, indicating a potential upside of 211.11%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than DURECT.
DURECT received 314 more outperform votes than 60 Degrees Pharmaceuticals when rated by MarketBeat users. Likewise, 60.89% of users gave DURECT an outperform vote while only 8.33% of users gave 60 Degrees Pharmaceuticals an outperform vote.
In the previous week, 60 Degrees Pharmaceuticals had 5 more articles in the media than DURECT. MarketBeat recorded 6 mentions for 60 Degrees Pharmaceuticals and 1 mentions for DURECT. DURECT's average media sentiment score of 1.89 beat 60 Degrees Pharmaceuticals' score of 0.93 indicating that DURECT is being referred to more favorably in the media.
Summary
60 Degrees Pharmaceuticals beats DURECT on 10 of the 18 factors compared between the two stocks.
Get 60 Degrees Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SXTP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
60 Degrees Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:SXTP) was last updated on 6/13/2025 by MarketBeat.com Staff
